Latest Boehringer Ingelheim Corporation Stories

RIDGEFIELD, Conn., Dec. 8, 2012 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced results from two new post-hoc sub-analyses comparing the clinical management and outcomes of patients who experienced major bleeding while treated with dabigatran or warfarin. These findings from the RE-LY® trial and four other Phase III trials report outcomes after a major bleed on dabigatran, despite the lack of a specific reversal agent, may be better than after a...

RIDGEFIELD, Conn., Nov. 29, 2012 /PRNewswire/ -- Boehringer Ingelheim today announced that new data evaluating volasertib, an investigational polo-like kinase (Plk) inhibitor, will be presented at the 54(th) American Society of Hematology (ASH) annual meeting taking place December 8-11 in Atlanta, Ga. Data include results from the Phase II portion of a Phase I/II study evaluating volasertib administered in addition to low-dose cytarabine (LDAC) compared to LDAC...

BOSTON and RIDGEFIELD, Conn., Nov. 10, 2012 /PRNewswire/ -- Final Phase 2b data from Boehringer Ingelheim's interferon (IFN)-free Phase 2b SOUND-C2 study showed that up to 85 percent of genotype 1b (GT1b) hepatitis C (HCV) patients achieved sustained virologic response (SVR or viral cure) 12 and 24 weeks after the end of treatment with the investigational treatment regimen of faldaprevir (BI 201335) and BI 207127, in combination with ribavirin (RBV). A viral cure was achieved for...

RIDGEFIELD, Conn., Nov. 9, 2012 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced the launch of HepCRedefined.com, an online portal to help improve the lives of those living with the hepatitis C virus (HCV) through education, information and understanding. HepCRedefined.com aims to redefine the HCV journey by providing downloadable and shareable resources to healthcare providers, advocates, caregivers and patients. To view the multimedia assets associated...

RIDGEFIELD, Conn., Nov. 7, 2012 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced interim results from the RELY-ABLE(®) trial, a long-term extension of the RE-LY(®) study. During more than two years of randomized follow-up, key safety outcomes such as major bleeding, total bleeding and life threatening bleeding were similar to the results of the dabigatran 110mg* and 150mg arms of the pivotal RE-LY trial that evaluated Pradaxa(®) (dabigatran etexilate...

RIDGEFIELD, Conn., Nov. 7, 2012 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. announced today that it is conducting a nationwide voluntary recall of a single manufacturing lot of Pradaxa(®) (dabigatran etexilate mesylate), 75mg 60 US, NDC 0597- 0149-54, lot 201900, Exp January 2015. PRADAXA is indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF). The recall is limited to this one lot number. (Photo:...

RIDGEFIELD, Conn., Nov. 2, 2012 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) today announced the results of a Mini-Sentinel assessment that indicates bleeding rates associated with new use of Pradaxa(®) (dabigatran etexilate mesylate) capsules do not appear to be higher than bleeding rates associated with new use of warfarin, which is consistent with observations from the pivotal RE-LY(®) trial. The Mini-Sentinel assessment evaluated new information about the risk of...

RIDGEFIELD, Conn., Oct. 30, 2012 /PRNewswire/ -- Boehringer Ingelheim will present data from 16 abstracts at the American Heart Association's (AHA) Scientific Sessions in Los Angeles from November 3 to 7, 2012, including data on Pradaxa(®) (dabigatran etexilate mesylate) capsules and data evaluating patients with non-valvular atrial fibrillation (NVAF). These data reinforce BI's commitment to adding to the scientific body of evidence for PRADAXA and stroke prevention in NVAF....

RIDGEFIELD, Conn., Oct. 29, 2012 /PRNewswire/ -- On average, every hour, 15 people in the United States (U.S.) will suffer a stroke caused by atrial fibrillation (AFib), a type of irregular heartbeat. In support of World Stroke Day, Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) has launched 15 Every Hour, a new campaign to educate people about the seriousness of AFib-related strokes, which are nearly twice as likely to be deadly or severely disabling as non-AFib-related strokes....

RIDGEFIELD, Conn., Oct. 1, 2012 /PRNewswire/ -- New data from Boehringer Ingelheim's hepatitis C virus (HCV) clinical development program, HCVerso(TM),( )have been accepted for presentation at the 63(rd) Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), taking place November 9 - 13 in Boston, MA. Results from all arms of SOUND-C2, a Phase 2b trial evaluating an investigational interferon-free HCV treatment, along with other analyses of the trial...